Preeclampsia and Defective Placentation in Oocyte Donation: Importance of HLA-C and KIR
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
AgeNot listed
SponsorUniversitair Ziekenhuis Brussel
About this trial
The IMMUN-OR study aims to study HLA-C/KIR combinations when looking at the risk of development of preeclampsia (PE) in pregnancies after oocyte donation. With the use of oocyte donation currently on the rise, the importance of identifying risk factors for the higher frequency of PE development is clear. Certain HLA-C/KIR combinations have already been linked to higher risk of obstetric complications. This study will look at these combinations within the specific situation of oocyte donation. This will further investigate the importance of the immunological interface when looking at PE. Participants will be chosen from a database of all the live births after oocyte donation at our center. The research team will contact the mother, child and donor. If all three agree to participate, they will be invited to our center, where the research team will take a cheek swab. This swab will then be used to isolate a DNA sample. With these samples, we can determine the HLA-C/KIR combination for each threesome. When all samples have been collected, two groups are made based off their health outcome: one group that did develop PE during their pregnancy, and one group that did not develop PE. The different HLA-C/KIR combinations will be compared, and the research team will look to discover if one combination is linked to a higher occurrence of PE development.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Every live birth delivery post oocyte donation (mother, child, donor).
Disqualifiers
Unknown HLA-C/KIR typing of acceptor, donor or offspring (resumlts of all 3 parties must be present to participate.
Trial population
Patients treated for oocyte donation at the Brussels IVF center.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
2,325 Participants
are grouped into 2 trial groupsGroup A: PE
Group B: No PE
Trial outcomes
Primary outcomes
1
Preeclampsia development.
The development of PE throughout the pregnancy conceived through oocyte donation.
Time frame
From 20 weeks gestation until 6 weeks postpartum.Secondary outcomes
1
Development of early onset PE versus late onset PE.
The development of PE before 34 weeks gestation (= early onset PE) or after 34 weeks of gestation (= late onset PE).
Time frame
From 20 weeks gestation until 6 weeks postpartum in pregnancies conceived through oocyte donation.2
Preterm PE versus Term PE or PP PE
Development of preterm PE (\<37 weeks gestation), term PE (\>37 weeks gestation) and postpartum PE (after birth) throughout a pregnancy conceived through oocyte donation.
Time frame
From 20 weeks gestation until 6 weeks postpartum in pregnancies conceived through oocyte donation.3
Incidence of eclampsia, placental abruption, HELLP syndrome
The occurence of eclampsia, placental abruption and HELLP syndrome in pregnancies conceived through oocyte donation.
Time frame
From conception until 6 weeks postpartum in pregnancies conceived through oocyte donation.4
Obstetrical complications
Incidence of obstetrical complications such as gestational hypertension, IUGR, PPROM, ...
Time frame
From conceptions until birth in pregnancies conceived through oocyte donation.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: